[HTML][HTML] Novel targeted therapies of T cell lymphomas
K Iżykowska, K Rassek, D Korsak… - Journal of Hematology & …, 2020 - Springer
T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas
(NHL) that often present at an advanced stage at the time of diagnosis and that most …
(NHL) that often present at an advanced stage at the time of diagnosis and that most …
Epigenetic alterations and advancement of lymphoma treatment
S Zhuang, Z Yang, Z Cui, Y Zhang, F Che - Annals of Hematology, 2024 - Springer
Lymphomas, complex and heterogeneous malignant tumors, originate from the
lymphopoietic system. These tumors are notorious for their high recurrence rates and …
lymphopoietic system. These tumors are notorious for their high recurrence rates and …
Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma
TB Nguyen, M Sakata-Yanagimoto, M Fujisawa… - Cancer research, 2020 - AACR
Abstract Recurrent hotspot (p. Gly17Val) mutations in RHOA encoding a small GTPase,
together with loss-of-function mutations in TET2 encoding an epigenetic regulator, are …
together with loss-of-function mutations in TET2 encoding an epigenetic regulator, are …
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma
N Parameswaran, L Luo, L Zhang, J Chen… - Leukemia, 2023 - nature.com
T cell lymphomas (TCL) are heterogeneous, aggressive, and have few available targeted
therapeutics. In this study, we determined that CD6, an established T cell marker, was …
therapeutics. In this study, we determined that CD6, an established T cell marker, was …
[HTML][HTML] New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
R Mhaidly, A Krug, P Gaulard, F Lemonnier, JE Ricci… - Oncogenesis, 2020 - nature.com
Mouse models are essential to study and comprehend normal and malignant
hematopoiesis. The ideal preclinical model should mimic closely the human malignancy …
hematopoiesis. The ideal preclinical model should mimic closely the human malignancy …
Biology and molecular pathogenesis of mature T-cell lymphomas
JR Cortés, T Palomero - Cold Spring …, 2021 - perspectivesinmedicine.cshlp.org
Peripheral T-cell lymphomas (PTCLs) constitute a highly heterogeneous group of
hematological diseases with complex clinical and molecular features consistent with the …
hematological diseases with complex clinical and molecular features consistent with the …
Pharmacoepigenetic processors: epigenetic drugs, drug resistance, toxicoepigenetics, and nutriepigenetics
R Cacabelos, JC Carril, A Sanmartín, P Cacabelos - Pharmacoepigenetics, 2019 - Elsevier
The pharmacoepigenetic apparatus is integrated by gene clusters of different categories,
including (i) pathogenic genes involved in disease pathogenesis,(ii) mechanistic genes …
including (i) pathogenic genes involved in disease pathogenesis,(ii) mechanistic genes …
Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
Y Sun, L Li, X Li, L Zhang, X Wang… - Therapeutic …, 2020 - journals.sagepub.com
Aim: To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P),
thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in …
thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in …
T time: Emerging and new therapies for peripheral T-cell lymphoma
Abstract Peripheral T-cell Lymphomas (PTCL) are a heterogenous group of aggressive non-
Hodgkin lymphomas that are far less sensitive to chemotherapy than their B-cell …
Hodgkin lymphomas that are far less sensitive to chemotherapy than their B-cell …
Lymph node fine‐needle cytology in the era of personalised medicine. Is there a role?
Abstract The 2016 World Health Organisation revised classification of lymphoma has sub‐
classified well‐defined entities and added a number of provisional entities on the basis of …
classified well‐defined entities and added a number of provisional entities on the basis of …